MedPath

Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Phase 2
Terminated
Conditions
Non-Hodgkin's Lymphoma
Registration Number
NCT00250861
Lead Sponsor
US Oncology Research
Brief Summary

The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good and bad) this drug combination has on NHL. Rituximab and aldesleukin are not approved in combination by the Food and Drug Administration (FDA) for the treatment of non-Hodgkins lymphoma; however, Rituximab is approved for use by itself to treat NHL.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
110
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (21)

Rocky Mountain Cancer Center-Midtown

🇺🇸

Denver, Colorado, United States

Hematology Oncology Associates of IL

🇺🇸

Chicago, Illinois, United States

Cancer Care & Hematology Specialists of Chicagoland

🇺🇸

Niles, Illinois, United States

Minnesota Oncology Hematology, PA

🇺🇸

Minneapolis, Minnesota, United States

Kansas City Cancer Centers-Central

🇺🇸

Kansas, Missouri, United States

Greater Dayton Cancer Center

🇺🇸

Kettering, Ohio, United States

Cancer Centers of the Carolinas

🇺🇸

Greenville, South Carolina, United States

Texas Cancer Center

🇺🇸

Arlington, Texas, United States

Texas Cancer Center at Medical City

🇺🇸

Dallas, Texas, United States

El Paso Cancer Treatment Ctr

🇺🇸

El Paso, Texas, United States

Scroll for more (11 remaining)
Rocky Mountain Cancer Center-Midtown
🇺🇸Denver, Colorado, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.